Literature DB >> 11156552

Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe.

R A Watts1, M A Gonzalez-Gay, S E Lane, C Garcia-Porrua, G Bentham, D G Scott.   

Abstract

OBJECTIVE: The aetiopathogenesis of the primary systemic vasculitides (PSV) is unknown but includes both environmental and genetic factors. The development of classification criteria/definitions for PSV allows comparison of the epidemiology between different regions.
METHODS: The same methods and the American College of Rheumatology (1990) criteria or Chapel Hill definitions were used to compare the epidemiology of Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, and polyarteritis nodosa in Norwich (east England population 413 500) and Lugo (northwest Spain population 204 100). Patients with PSV were identified between 1 January 1988 and 31 December 1998.
RESULTS: Overall, the incidence of PSV in adults was almost equal in Norwich (18.9/million) and Spain (18.3/million). The incidence of Wegener's granulomatosis in Norwich (10.6/million) was greater than in Spain (4.9/million). There was a marked age-specific increase in incidence in Norwich with a peak age 65-74 years (52.9/million), but a virtually equal age distribution between ages 45 and 74 in Lugo (34.1/million). There was no significant increase with time in either population, or evidence of cyclical changes in incidence.
CONCLUSION: These data support the suggestion that environmental factors may be important in the pathogenesis of PSV.

Entities:  

Mesh:

Year:  2001        PMID: 11156552      PMCID: PMC1753459          DOI: 10.1136/ard.60.2.170

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  44 in total

1.  B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer.

Authors:  Lucius Bader; Wenche Koldingsnes; Johannes Nossent
Journal:  Clin Rheumatol       Date:  2010-06-28       Impact factor: 2.980

Review 2.  Granulomatosis with polyangiitis in childhood.

Authors:  Marinka Twilt; Susanne Benseler; David Cabral
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

3.  Epidemiology of giant cell arteritis in an Arab population: a 22-year study.

Authors:  Neil R Miller
Journal:  Br J Ophthalmol       Date:  2007-06       Impact factor: 4.638

4.  ANCA-associated vasculitis in Hispanic Americans: an unrecognized severity.

Authors:  Antoine G Sreih; Ranadeep Mandhadi; Fadi Aldaghlawi; Asad Khan; Vajiha Irshad; Katherine Finn; Joel A Block
Journal:  Clin Rheumatol       Date:  2014-04-22       Impact factor: 2.980

Review 5.  French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides).

Authors:  Benjamin Terrier; Raphaël Darbon; Cécile-Audrey Durel; Eric Hachulla; Alexandre Karras; Hélène Maillard; Thomas Papo; Xavier Puechal; Grégory Pugnet; Thomas Quemeneur; Maxime Samson; Camille Taille; Loïc Guillevin
Journal:  Orphanet J Rare Dis       Date:  2020-12-29       Impact factor: 4.123

Review 6.  Pathogenesis of ANCA-associated vasculitis.

Authors:  Rodrigo Cartin-Ceba; Tobias Peikert; Ulrich Specks
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

7.  HSP or not HSP... that is the question.

Authors:  David Cordiner; Clair A Evans; John Morrice
Journal:  BMJ Case Rep       Date:  2010-12-03

Review 8.  Genetics of ANCA-associated Vasculitides.

Authors:  Manuel F Ugarte-Gil; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2014-07       Impact factor: 4.592

9.  A case of polyarteritis nodosa presenting initially as peripheral vascular disease.

Authors:  Serge De Golovine; Sameer Parikh; Lee Lu
Journal:  J Gen Intern Med       Date:  2008-06-17       Impact factor: 5.128

10.  Stable incidence of systemic vasculitides in schleswig-holstein, Germany.

Authors:  Karen Herlyn; Bernhard Hellmich; Wolfgang L Gross; Eva Reinhold-Keller
Journal:  Dtsch Arztebl Int       Date:  2008-05-09       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.